Wouters Anke, Lemmens Robin, Christensen Soren, Wilms Guido, Dupont Patrick, Mlynash Michael, Schneider Armin, Laage Rico, Cereda Carlo W, Lansberg Maarten G, Albers Gregory W, Thijs Vincent
KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium VIB, Vesalius Research Center, Laboratory of Neurobiology, Leuven, Belgium University Hospitals Leuven, Department of Neurology, Leuven, Belgium
KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium VIB, Vesalius Research Center, Laboratory of Neurobiology, Leuven, Belgium University Hospitals Leuven, Department of Neurology, Leuven, Belgium.
Int J Stroke. 2016 Jan;11(1):127-33. doi: 10.1177/1747493015607503.
Recent trials have shown a clear benefit of endovascular therapy for stroke patients presenting within 6 h after stroke onset. Imaging-based selection may identify a cohort with a favorable response to endovascular therapy, in an even later time window.
We performed an indirect comparison between outcomes seen in DEFUSE 2, a prospective cohort study of patients who received a baseline MRI before endovascular therapy, and a control group from AXIS 2 receiving standard medical care up to 12 h after symptom onset.
Patients from AXIS 2 with a confirmed large vessel occlusion were selected as a control group for DEFUSE 2-patients. The primary endpoint was good functional outcome at day 90 (Modified Rankin Score 0-2). We performed a stratified analysis based on the presence of the target mismatch for both studies and reperfusion status in DEFUSE 2.
We compared good functional outcome in 108 patients from AXIS 2 and 99 patients from DEFUSE 2. In DEFUSE 2-patients with the target mismatch profile in whom reperfusion was achieved, the rate of good functional outcome was increased compared to target mismatch patients in AXIS 2, 54% versus 29% (OR 3.2, 95% CI 1.1-9.4). In target mismatch patients treated between 6 and 12 h after stroke onset, this association between study and good functional outcome remained present (OR 9.0, 95% CI 1.1-75.8).
This indirect comparison suggests that endovascular treatment resulting in substantial reperfusion is associated with improved outcome in target mismatch patients even beyond 6 h after stroke onset. Confirmation is needed from future clinical trials that randomize patients beyond the 6 h time window.
近期试验表明,血管内治疗对卒中发病后6小时内就诊的患者有明显益处。基于影像学的选择可能会在更晚的时间窗内识别出对血管内治疗有良好反应的队列。
我们对DEFUSE 2(一项对血管内治疗前接受基线MRI检查的患者进行的前瞻性队列研究)和AXIS 2中症状发作后12小时内接受标准医疗护理的对照组的结果进行了间接比较。
将AXIS 2中确诊为大血管闭塞的患者选为DEFUSE 2患者的对照组。主要终点是90天时的良好功能结局(改良Rankin量表评分0 - 2分)。我们根据两项研究中目标不匹配的存在情况以及DEFUSE 2中的再灌注状态进行了分层分析。
我们比较了AXIS 2的108例患者和DEFUSE 2的99例患者的良好功能结局。在DEFUSE 2中实现再灌注的具有目标不匹配特征的患者中,与AXIS 2中的目标不匹配患者相比,良好功能结局的发生率有所增加,分别为54%和29%(比值比3.2,95%置信区间1.1 - 9.4)。在卒中发作后6至12小时接受治疗的目标不匹配患者中,研究与良好功能结局之间的这种关联仍然存在(比值比9.0,95%置信区间1.1 - 75.8)。
这种间接比较表明,即使在卒中发作后6小时以上,导致大量再灌注的血管内治疗与目标不匹配患者的结局改善相关。未来需要进行临床试验来证实,将患者随机分组至6小时时间窗以外的情况。